RWD Study in HER2+ mBC Patients in Third-Line Therapy

Status Completed

Clinical Trial Summary

This retrospective observational study will collect Canadian real-world data (RWD) from HER2+ metastatic breast cancer (mBC) patients to describe treatment sequences of all therapies received in the metastatic setting, to measure overall survival (OS), progression free survival (PFS), time to next active anti-cancer therapy, and to estimate the health resources utilization (HRU) during third-line therapy.

Clinical Trial Description

The proportion of treatment received during all lines of therapy in the metastatic setting will be described. The 2-year survival rate and median OS with interquartile range (IQR) for third-line therapy will be calculated. HRU data and costs during third-line therapy will be collected. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04566458
Study type	Observational
Source	Exactis Innovation
Contact
Status	Completed
Phase
Start date	October 1, 2020
Completion date	May 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04469127` - A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.	Phase 1/Phase 2
Withdrawn	`NCT03032614` - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients	Phase 2
Withdrawn	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05377047` - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer	N/A
Completed	`NCT03304210` - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer	Phase 1
Completed	`NCT05054374` - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT05559528` - BRaziLian outcomE for metAStatic breasT Cancer
Active, not recruiting	`NCT05090358` - Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05033925` - Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT03401359` - The Resistance and Immune Response to Palbociclib in Breast Cancer	N/A
Active, not recruiting	`NCT03870919` - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients	N/A
Not yet recruiting	`NCT05860907` - Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis	Phase 4
Completed	`NCT00393341` - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer	N/A
Recruiting	`NCT05625087` - Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib	Phase 2
Recruiting	`NCT06075810` - A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer	Phase 1
Recruiting	`NCT04697043` - The Benefit of Surgery in Stage IV of Breast Cancer	N/A
Recruiting	`NCT05837533` - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients	N/A
Active, not recruiting	`NCT03324425` - Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05670054` - Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients	Phase 3
Terminated	`NCT03202446` - Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer	Phase 3